Ask AI

TROP2-Directed ADCs in mTNBC: Personalizing Treatment Sequencing and Supportive Care

Text Module
Text Module Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: September 18, 2026

Expiration: March 17, 2027

See Activity Collection

In this text module, an expert examines the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in metastatic triple-negative breast cancer (mTNBC), with a focus on evidence guiding treatment selection and sequencing, emerging strategies for sequential ADC use, and practical approaches for preventing and managing treatment-related adverse events such as neutropenia, diarrhea, oral mucositis/stomatitis, ocular toxicities, and ILD/pneumonitis. The activity also highlights how biomarker status, prior therapy, toxicity profiles, and access-related factors influence individualized treatment decisions in clinical practice.

TROP2 ADC Sequencing and Safety in mTNBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

 During counseling about possible adverse events (AEs) and their management with sacituzumab govitecan, all of the following would be appropriate to explain to a patient EXCEPT which one?